Chemoprevention of severe neonatal hyperbilirubinemia.
The uses of synthetic heme analogues that are competitive inhibitors of heme oxygenase, the rate-limiting enzyme in the production of bilirubin, represent a novel means of controlling severe hyperbilirubinemia in the newborn. The logic of this approach and the use of stannsoporfin (tin mesoporphyrin) as the compound of choice are discussed.
Drummond
George S
GS
The Rockefeller University Hospital, New York, NY, USA.
Kappas
Attallah
A
D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006419:Heme Oxygenase (Decyclizing) / Q000037:antagonists & inhibitors*; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000517:prevention & control*; D008665:Metalloporphyrins / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D008665:Metalloporphyrins; C055421:tin mesoporphyrin; D006419:Heme Oxygenase (Decyclizing)